Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28963070 | 1.00 | HTT (0.58) | HTTCYP2D6CA1CA2ACHE | |
| SCHEMBL2465466 | 0.86 | ALDH1A1 (0.51) | HTTCYP2D6CA1CA2ACHE | |
| SCHEMBL3610280 | 0.84 | HTT (0.59) | HTTCYP2D6CA1CA2ACHE | |
| SCHEMBL3411434 | 0.83 | ACHE (0.47) | HTTACHEMEN1KMT2AMAPK1 | |
| SCHEMBL3641536 | 0.83 | HTT (0.40) | HTTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4981765 | 0.82 | HTT (0.66) | HTTCYP2D6CA1CA2ACHE | |
| SCHEMBL3637979 | 0.81 | ALDH1A1 (0.40) | HTTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3417280 | 0.81 | ERN1 (0.40) | HTTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL20551547 | 0.81 | HTT (0.42) | HTTCYP2D6CA1CA2ACHE | |
| SCHEMBL23674808 | 0.81 | ALDH1A1 (0.41) | HTTCA1CA2ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970204-A1 | PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation For Research Development (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160181-A1 | PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012164572-A1 | SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-12-06 | — | — | WO | disclosed |
| EP-2265606-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2227466-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1465860-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF ( ) 2-AMINO-N-[2,(S,5-DIMETHOXYPHENYL)-2-HYDROXYETHYL] ACETAMIDE MONOHYDROCHLORIDE | Sanmar Speciality Chemicals Ltd (IN) | 2004-10-13 | — | — | EP | disclosed |
| EP-1465860-A4 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF ( ) 2-AMINO-N-[2,(S,5-DIMETHOXYPHENYL)-2-HYDROXYETHYL] ACETAMIDE MONOHYDROCHLORIDE | SANMAR SPECIALITY CHEMICALS LT (IN) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004018409-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF (±) 2-AMINO-N-[2,(S,5-DIMETHOXYPHENYL)-2-HYDROXYETHYL] ACETAMIDE MONOHYDROCHLORIDE | SANMAR SPECIALITY CHEMICALS LTD (IN) | 2004-03-04 | — | — | WO | disclosed |
| EP-0099329-A1 | Dithio compounds, pharmaceutical preparations containing them and their use | Zyma SA (CH) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | HTT 3858/4885CYP2D6 881/4885CA1 1877/4885 |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | CXCR1, NLRP3, NLRP1 | HTT 3858/4885CYP2D6 881/4885CA1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.